Merontos, Ruby Jean L.
HRN: 22-71-08 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/02/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/02/2023
05/08/2023
IV
68mg
OD
Pcap Severe
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes